SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parmax Pharma - Quaterly Results

14 Aug 2025 Evaluate
The Sales for the quarter ended June 2025 of Rs. 19.42 million declined by -75.15% from Rs. 78.16 millions.The Net Loss for the quarter ended June 2025 is Rs. -7.65 millions as compared to Net Profit of Rs. 0.13 millions of corresponding quarter ended June 2024Operating profit Margin for the quarter ended June 2025 slipped to -2.44% as compared to 5.22% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 19.42 78.16 -75.15 19.42 78.16 -75.15 282.04 110.53 155.17
Other Income 0.07 0.08 -12.50 0.07 0.08 -12.50 0.40 0.48 -16.67
PBIDT -2.44 5.22 -146.74 -2.44 5.22 -146.74 2.94 -33.23 -108.85
Interest 2.80 1.13 147.79 2.80 1.13 147.79 5.86 6.22 -5.79
PBDT -5.24 4.09 -228.12 -5.24 4.09 -228.12 -13.64 -39.45 -65.42
Depreciation 2.41 3.96 -39.14 2.41 3.96 -39.14 10.32 17.12 -39.72
PBT -7.65 0.13 -5984.62 -7.65 0.13 -5984.62 -23.96 -56.57 -57.65
TAX 0.00 0.00 0.00 0.00 0.00 0.00 -3.01 0.95 -416.84
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 -3.01 0.95 -416.84
PAT -7.65 0.13 -5984.62 -7.65 0.13 -5984.62 -20.95 -57.52 -63.58
Equity 37.41 37.41 0.00 37.41 37.41 0.00 37.41 37.41 0.00
PBIDTM(%) -12.56 6.68 -288.13 -12.56 6.68 -288.13 1.04 -30.06 -103.47

Parmax Pharma Share Price

30.03 -0.62 (-2.02%)
13-Apr-2026 11:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.95
Dr. Reddys Lab 1223.60
Cipla 1213.85
Zydus Lifesciences 923.70
Lupin 2320.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×